SynBioBeta

32.4K posts

SynBioBeta banner
SynBioBeta

SynBioBeta

@SynBioBeta

Biologize the Future Join us May 4-7, 2026 - San Jose Convention Center, California https://t.co/8lLUroYKhk and sign up for our newsletter https://t.co/NnsHTMR0m3

شامل ہوئے Ağustos 2012
3.9K فالونگ52.6K فالوورز
SynBioBeta
SynBioBeta@SynBioBeta·
Human genomics is changing drug discovery by helping teams understand disease with greater precision from the start 💊🔍 🧬 SynBioBeta • May 4–7, 2026 • San Jose 📍 Join 2,000+ leaders shaping the future of biotech. Get your tickets to SynBioBeta 2026 before prices go up → Register and join the conversation at SynBioBeta syntheticbiologysummit.com/?utm_source=x&… #SynBioBeta #Biomanufacturing #Engineering #StartupLife #SyntheticBiology
English
0
2
1
127
SynBioBeta
SynBioBeta@SynBioBeta·
Breakout Ventures has secured $114 million for its Fund III, targeting seed-stage investments in companies harnessing AI to tackle complex scientific challenges. The fund's launch follows notable successes, including the $400 million acquisition of Surf Bio by Halozyme, and initial investments in startups like Reach Industries and a stealth University of Chicago spinout focused on small molecule discovery. businesswire.com/news/home/2026… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…
SynBioBeta tweet media
English
0
2
2
122
SynBioBeta
SynBioBeta@SynBioBeta·
President Trump nominates Jim O’Neill, former HHS deputy secretary and acting CDC director, to lead the National Science Foundation for a six-year term, filling a vacancy that has persisted for nearly 10 months. O’Neill's extensive background in health and science policy positions him to steer the NSF's funding for basic research and education in the U.S. if confirmed by the Senate. executivegov.com/articles/jim-o… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…
SynBioBeta tweet media
English
0
0
0
128
SynBioBeta
SynBioBeta@SynBioBeta·
Ginkgo Bioworks has officially launched Ginkgo Cloud Lab, an innovative platform enabling researchers to conduct experiments via a web browser using the company's autonomous lab infrastructure. This platform features AI-driven compatibility assessments and remote access to over 70 lab instruments, marking a strategic shift toward fully automated R&D services while inviting collaboration from academia and the biopharmaceutical industry. prnewswire.com/news-releases/… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…
SynBioBeta tweet media
English
2
1
9
285
SynBioBeta
SynBioBeta@SynBioBeta·
PlasmaLeap Technologies has raised A$30 million (US$20 million) in Series A funding, led by the Gates Foundation, Investible, and Yara Growth Ventures, to develop innovative fertilizer hubs in New South Wales and Tasmania. Their patented reactor technology enables on-farm production of ammonia and nitric acid using only air, water, and renewable electricity, aiming to significantly reduce agricultural emissions and reliance on traditional supply chains. igrownews.com/plasmaleap-tec… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…
SynBioBeta tweet media
English
0
0
0
102
SynBioBeta
SynBioBeta@SynBioBeta·
GSK has finalized a $950 million cash deal to acquire Canadian biotech 35Pharma, aiming to strengthen its portfolio with the experimental pulmonary hypertension treatment HS235. This acquisition comes as CEO Luke Miels seeks to address patent expirations on key HIV drugs and reinforces GSK's focus on obesity-related health conditions, an increasingly crowded market. reuters.com/legal/transact… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…
SynBioBeta tweet media
English
0
1
1
114
SynBioBeta
SynBioBeta@SynBioBeta·
Paris-based biotech startup baCta has raised €7 million in Seed funding led by LocalGlobe and Daphni, with aims to scale its AI-driven bioproduction of astaxanthin, an antioxidant used in health and cosmetics. The company plans to leverage its proprietary yeast strain and advanced synthetic biology techniques to achieve competitive unit economics and enhance resilience in the supply chain for industrial ingredients. eu-startups.com/2026/03/paris-… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…
SynBioBeta tweet media
English
0
2
3
94
SynBioBeta
SynBioBeta@SynBioBeta·
Generate Biomedicines has priced its shares at $16, successfully raising $400 million in its U.S. IPO, with 25 million shares sold. The company, known for its AI-driven drug discovery platform, focuses on developing protein-based therapies in immunology and oncology, including its lead candidate GB-0895 for severe asthma, currently in late-stage trials. Trading under the ticker "GENB" on Nasdaq begins Friday. reuters.com/business/healt… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…
SynBioBeta tweet media
English
0
2
2
225
SynBioBeta
SynBioBeta@SynBioBeta·
In a strategic move to enhance its oncology portfolio, Gilead Sciences has agreed to acquire Arcellx for an implied equity value of $7.8 billion, securing full ownership of the late-stage CAR T therapy anitocabtagene autoleucel (anito-cel). This acquisition consolidates Arcellx's innovative D-Domain platform with Gilead's established cell therapy infrastructure, positioning the company to accelerate development and commercialization efforts ahead of the therapy's FDA decision expected by December 2026. news.biobuzz.io/2026/02/23/bre… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…
SynBioBeta tweet media
English
0
3
4
495
SynBioBeta
SynBioBeta@SynBioBeta·
Manus has expanded its partnership with the U.S. Department of Health and Human Services, receiving an additional $15 million to enhance domestic production of shikimic acid, a vital component for oseltamivir, the active ingredient in Tamiflu. This funding aims to strengthen U.S. health security by reducing reliance on foreign supply chains, addressing a critical vulnerability, as over 80% of essential medicine ingredients are sourced overseas. manusbio.com/articles/manus… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…
SynBioBeta tweet media
English
2
4
3
472
SynBioBeta
SynBioBeta@SynBioBeta·
Turbine has raised $25 million in a Series B round led by Interactive Venture Partners, with participation from Beiersdorf Venture Capital and other existing investors. The funding will enhance Turbine's virtual cell platform and support a new partnership with a top 10 pharmaceutical company to model immune cell behavior, aiming to streamline the discovery of novel immunotherapy combinations. prnewswire.com/news-releases/… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…
SynBioBeta tweet media
English
0
4
3
429
SynBioBeta
SynBioBeta@SynBioBeta·
JOYN Foods , formerly Mush Foods, plans to triple revenues in 2026 and achieve EBITDA positivity by early 2027, leveraging its cost-effective mycelium-based meat blends to capture the price-sensitive foodservice market. With monthly sales exceeding $250k and partnerships with major suppliers like Sysco and US Foods, JOYN's 50CUT brand is gaining traction in K-12 cafeterias following recent approval from the South Carolina Purchasing Alliance. agfundernews.com/hybrid-meat-fo… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…
SynBioBeta tweet media
English
1
2
2
342
SynBioBeta ری ٹویٹ کیا
SynBioBeta
SynBioBeta@SynBioBeta·
French startup Verley has raised €32M ($37.6M) in Series A funding to scale production of its precision-fermented, cow-free whey proteins, targeting the U.S. market with initial product launches by the end of 2026. The oversubscribed round was led by Alven, with additional backing from Bpifrance and others, positioning Verley to meet increasing demand for high-protein alternatives amid a tightening supply of conventional whey. greenqueen.com.hk/verley-precisi… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…
SynBioBeta tweet media
English
0
3
2
365